Rare Solid Tumors of the Pancreas as Differential Diagnosis of Pancreatic Adenocarcinoma

Sabine Kersting¹, Monika S Janot¹, Johanna Munding², Dominique Suelberg¹, Andrea Tannapfel², Ansgar M Chromik¹, Waldemar Uhl¹, Uwe Bergmann¹

Departments of ¹General and Visceral Surgery, St. Josef-Hospital, and ²Pathology; Ruhr-University Bochum. Bochum, Germany

ABSTRACT

Context Rare solid tumors of the pancreas can be misinterpreted as primary pancreatic cancer. Objective The aim of this study was to report our experience in the treatment of patients with rare benign and malignant tumors of the pancreas, treated in our division from January 2004 to August 2010, were analyzed retrospectively. Design Data from patients of our prospective data-base with rare benign and malignant tumors of the pancreas, treated in our division from January 2004 to August 2010, were analyzed retrospectively. Results One-thousand and ninety-eight patients with solid tumors of the pancreas underwent pancreatic surgery. In 19 patients (10 women, 9 men) with a mean age of 57 years (range: 20-74 years) rare pancreatic tumors (metastasis, solid pseudopapillary tumor, teratoma, hemangioma, accessory spleen, lymphoepithelial cyst, hamartoma, sarcoidosis, yolk sac tumor) were the reason for surgical intervention. Conclusion If rare benign and malignant pancreatic tumors, intrapancreatic metastasis, as well as pancreatic malformations or other abnormalities, present themselves as solid masses of the pancreas, they constitute an important differential diagnosis to primary pancreatic neoplasia, e.g. pancreatic ductal adenocarcinoma. Clinical imaging techniques cannot always rule out malignancy, thus operative exploration often remains the treatment of choice to provide the correct diagnosis and initiate adequate surgical therapy.

INTRODUCTION

Primary pancreatic ductal adenocarcinoma accounts for 85 to 90% of all pancreatic tumors [1]. Because of the aggressive behavior of pancreatic cancer - even after curative resection - the prognosis of primary pancreatic ductal adenocarcinoma is poor [2]. A variety of non-neoplastic conditions may form solid masses in the pancreas that may mimic primary pancreatic ductal adenocarcinoma [3]. Also some less common tumors of the pancreas, i.e. solid pseudopapillary tumors, acinar cell carcinoma, lymphoplasmatic sclerosing pancreatitis or primary pancreatic lymphoma, represent a small group of tumors that can be misinterpreted as primary pancreatic ductal adenocarcinoma [4]. Furthermore metastatic tumors to the pancreas are rare accounting for 1-2% of all pancreatic malignant tumors [5, 6]. When there is no widespread metastatic disease and the metastasis consists of an isolated mass in the pancreas, primary pancreatic ductal adenocarcinoma cannot be excluded. In patients with primary pancreatic ductal adenocarcinoma, curative resection has been considered the only treatment modality although long term survival is still poor. Rare tumors mimicking primary pancreatic ductal adenocarcinoma may also present as solid intrapancreatic masses, and despite of advances in imaging techniques, malignancy often cannot be ruled out without operative exploration and sampling of biopsies. In this study, we report our experience in the treatment of patients with rare benign and malignant tumors of the pancreas, intrapancreatic metastasis, pancreatic malformations and abnormalities. The clinical and pathological characteristics are described and discussed in the context of the role of surgery in patients with rare tumors of the pancreas.

MATERIAL AND METHODS

Patients

From January 2004 to August 2010, 1,616 patients underwent operations of the pancreas at our hospital, which is a specialized pancreas centre. In 1,098 patients a solid tumor of the pancreas was the indication for surgical intervention. 1,098 patients a solid tumor of the pancreas was the indication for surgical intervention. Clinicopathological data were entered into a prospective database. The database was analyzed for the incidence of rare solid...
tumors to the exclusion of primary pancreatic ductal adenocarcinoma and neuroendocrine tumors. Nineteen patients (10 women; 9 men; 1.2% of the pancreatic surgery population) in the mean age of 57 years (range: 20-74 years) underwent pancreatic surgery for rare tumors of the pancreas that clinically mimicked pancreatic cancer. In all patients preoperative gastroscopy, transabdominal ultrasound, laboratory tests including tumor markers (CEA, CA 19-9), oral glucose tolerance test, stool elastase and computed tomography (CT) were performed. Magnetic resonance imaging, endoscopic ultrasound and fine needle aspiration were carried out when indicated. Intraoperative frozen sections were performed and the resected specimen or taken biopsies were worked-up histologically by a gastrointestinal pathologist. For patients with malignant tumors of the pancreas further therapy was discussed in the interdisciplinary oncology conference of our hospital and a specific oncologic therapy was proposed. After discharge, patients were seen for follow up examinations in intervals of 3 or 6 months.

STATISTICS

Descriptive statistics only were used: frequencies, mean and range.

ETHICS

The patients were managed according to the ethical guidelines of the “World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects” adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the 59th WMA General Assembly, Seoul, South Korea, October 2008. No a priori approval by the appropriate institutional review committee of the study protocol was needed because the data were collected during the usual clinical practice. Patients gave oral or written informed consent according to the usual clinical practice.

RESULTS

Among 19 patients with rare tumors of the pancreas other than primary pancreatic ductal adenocarcinoma or neuroendocrine tumors, 8 patients (42.1%) were symptomatic and developed the following symptoms that led to further diagnostics: abdominal pain (n=4), jaundice (n=2), diarrhea (n=1), B symptoms: fever, night sweats, weight loss (n=1). In the remaining 11 patients (57.9%) the tumors were incidentally diagnosed. Pathologically elevated CA 19-9 levels were found in 6 patients (31.6%) and CEA levels were found in 1 patient (5.3%) (Table 1).

After completion of staging diagnostics, metastatic disease to the pancreas was assumed in 6 patients (31.6%) who had been previously treated for renal carcinoma (n=3), breast cancer (n=1), melanoma (n=1) and in one patient with duodenal gastrinoma. In one patient a solid pseudopapillary tumor of the pancreas was suspected and in one patient a neuroendocrine tumor of the pancreas. The majority of patients (n=11; 57.9%) presented with an intrapancreatic mass that was suspicious for pancreatic cancer (Table 1).

Preoperative imaging in all patients revealed a solid intrapancreatic mass, thus malignancy could not be excluded. Before referral to our clinic, in 6 patients (31.6%) endoscopic ultrasound and fine needle aspiration of the tumor and in one patient (5.3%) preoperative puncction of the tumor was considered.

Table 1. Preoperative data of 19 patients with rare benign and malignant tumors of the pancreas.

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (y)</th>
<th>Gender</th>
<th>Symptoms</th>
<th>Previous treatment for carcinoma</th>
<th>Family History of pancreatic carcinoma</th>
<th>CA 19-9 (U/ml)</th>
<th>CEA (ng/ml)</th>
<th>Preoperative puncction of the tumor</th>
<th>Preoperative Suspicion diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>68</td>
<td>M</td>
<td>None</td>
<td>Positive</td>
<td>Elevated</td>
<td>0</td>
<td>FNA: No tumor cells</td>
<td>Pancreatic cancer</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>45</td>
<td>F</td>
<td>Abdominal pain</td>
<td>Breast cancer</td>
<td>Negative</td>
<td>Elevated</td>
<td>Elevated</td>
<td>No</td>
<td>Breast cancer with pancreatic and hepatic metastasis</td>
</tr>
<tr>
<td>3</td>
<td>69</td>
<td>F</td>
<td>None</td>
<td>Negative</td>
<td>Elevated</td>
<td>0</td>
<td>0</td>
<td>No</td>
<td>Pancreatic cancer</td>
</tr>
<tr>
<td>4</td>
<td>42</td>
<td>F</td>
<td>Abdominal pain</td>
<td>Malignant melanoma</td>
<td>Negative</td>
<td>0</td>
<td>0</td>
<td>FNA: No tumor cells</td>
<td>Pancreatic metastasis of Malignant melanoma</td>
</tr>
<tr>
<td>5</td>
<td>55</td>
<td>F</td>
<td>Diarrhea</td>
<td>None</td>
<td>Negative</td>
<td>0</td>
<td>0</td>
<td>No</td>
<td>Pancreatic metastasis of gastrinoma</td>
</tr>
<tr>
<td>6</td>
<td>67</td>
<td>F</td>
<td>B-symptoms</td>
<td>None</td>
<td>Negative</td>
<td>Elevated</td>
<td>0</td>
<td>FNA: No tumor cells</td>
<td>Pancreatic metastasis of bronchial carcinoma</td>
</tr>
<tr>
<td>7</td>
<td>64</td>
<td>M</td>
<td>No symptoms</td>
<td>Renal cell carcinoma</td>
<td>Negative</td>
<td>0</td>
<td>0</td>
<td>No</td>
<td>Pancreatic metastasis of renal cell carcinoma</td>
</tr>
<tr>
<td>8</td>
<td>57</td>
<td>F</td>
<td>Jaundice</td>
<td>None</td>
<td>Negative</td>
<td>0</td>
<td>0</td>
<td>FNA: No tumor cells</td>
<td>Pancreatic cancer</td>
</tr>
<tr>
<td>9</td>
<td>72</td>
<td>F</td>
<td>Abdominal pain</td>
<td>Renal cell carcinoma</td>
<td>Negative</td>
<td>Elevated</td>
<td>0</td>
<td>No</td>
<td>Pancreatic cancer</td>
</tr>
<tr>
<td>10</td>
<td>57</td>
<td>M</td>
<td>None</td>
<td>Negative</td>
<td>0</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>Pancreatic cancer</td>
</tr>
<tr>
<td>11</td>
<td>67</td>
<td>M</td>
<td>None</td>
<td>Negative</td>
<td>0</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>Pancreatic cancer</td>
</tr>
<tr>
<td>12</td>
<td>69</td>
<td>F</td>
<td>Abdominal pain</td>
<td>Renal cell carcinoma</td>
<td>Negative</td>
<td>Elevated</td>
<td>0</td>
<td>FNA: Metastasis of renal cell carcinoma</td>
<td>Pancreatic metastasis of renal cell carcinoma</td>
</tr>
<tr>
<td>13</td>
<td>28</td>
<td>M</td>
<td>None</td>
<td>Negative</td>
<td>0</td>
<td>0</td>
<td>FNA: SPT</td>
<td>SPT</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>58</td>
<td>M</td>
<td>None</td>
<td>Negative</td>
<td>Elevated</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>Pancreatic cancer</td>
</tr>
<tr>
<td>15</td>
<td>51</td>
<td>F</td>
<td>None</td>
<td>Negative</td>
<td>0</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>Neuroendocrine tumor of the pancreas</td>
</tr>
<tr>
<td>16</td>
<td>53</td>
<td>M</td>
<td>None</td>
<td>Negative</td>
<td>0</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>Pancreatic cancer</td>
</tr>
<tr>
<td>17</td>
<td>67</td>
<td>M</td>
<td>None</td>
<td>Positive</td>
<td>0</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>Pancreatic cancer</td>
</tr>
<tr>
<td>18</td>
<td>74</td>
<td>M</td>
<td>Painful jaundice</td>
<td>None</td>
<td>Negative</td>
<td>0</td>
<td>0</td>
<td>Laparoscopy: No tumor cells</td>
<td>Pancreatic cancer</td>
</tr>
<tr>
<td>19</td>
<td>20</td>
<td>F</td>
<td>None</td>
<td>Positive</td>
<td>0</td>
<td>0</td>
<td>No</td>
<td>No</td>
<td>Pancreatic cancer</td>
</tr>
</tbody>
</table>

F: female; FNA: fine needle aspiration; M: male; SPT: solid papillary tumor
In only two cases (by fine needle aspiration; 10.5%) atypical cells could be separated that preoperatively lead to the diagnoses of a solid pseudopapillary tumor of the pancreas and a pancreatic metastasis of a renal cell carcinoma. Thus, before surgery a correct preoperative diagnosis of the tumor was only made in two patients (10.5%). In the remaining 17 patients (89.5%) operation was necessary to affirm the diagnosis and to supply the patient the optimal therapy (Table 1).

Surgical intervention was carried out with different intentions. Ten patients (52.6%) were resected with curative intent. In 4 patients (21.1%) palliative tumor debulking and in one patient (5.3%) bypass operation were performed. Solely sampling of biopsies for histologic confirmation of tumor entity was done in 4 patients (21.1%) (Table 2).

Postoperative histological examination of the resected specimen or taken biopsies revealed pancreatic metastases of extrapancreatic malignomas (Figure 1) in 8 patients (renal cell carcinoma, n=3; melanoma, n=2; duodenal gastrinoma, n=1; breast cancer, n=1; retroperitoneal liposarcoma, n=1). In 10 patients (52.6%) the following rare benign tumors were detected: solid pseudopapillary tumor of the pancreas (n=3) (Figure 2), mature teratoma of the pancreas (n=2) (Figure 3), capillary hemangioma of the pancreas (n=1) (Figure 4), intrapancreatic accessory spleen (n=1) (Figure 5), lymphoepithelial cyst of the pancreas (n=1) (Figure 6), hamartoma of the pancreas (n=1) (Figure 7), and pancreatic sarcoidosis (n=1). In one patient an advanced yolk sac tumor of the pancreas with peritoneal carcinosis was diagnosed (Table 2).
Postoperative complications occurred in 8 patients (42.1%). One patient needed operative revision following pancreatic grade B fistula [7]. Three more patients were treated by minimal invasive interventions following pancreatic grade B fistula, intra-abdominal abscess and iatrogenic lesion of the ureter. Wound infection, pneumonia and renal failure regressed under conservative treatment. Two patients died during the postoperative course (10.5%). One patient with pancreatic metastasis of a renal cell carcinoma died following postoperative bleeding from the splenic artery. Another patient with pancreatic metastasis of a melanoma died of tumor progression (Table 2).

**DISCUSSION**

Advancement of imaging techniques and the improved awareness of clinical and pathological features of pancreatic neoplasms increasingly lead to the detection of rare solid intrapancreatic neoplasms that are difficult to differentiate from primary pancreatic ductal adenocarcinoma or neuroendocrine tumors. From 2004 to 2010 we operated 19 patients with rare pancreatic neoplasms. After extended preoperative diagnostics in the majority of patients (n=11) pancreatic cancer was suspected. Two of these patients presented with elevated tumor markers (Table 1), two other patients with jaundice and three patients reported a positive family history of pancreatic carcinoma. At other medical institutions endoscopic ultrasound and fine needle biopsy were done in two patients and diagnostic laparoscopy was done in one patient without any histological evidence. At our institution, intraoperative examination of frozen sections of the resected specimens and postoperative histological investigations excluded pancreatic cancer and detected in 10 patients the below described rare benign pancreatic tumors. In a 68-year-old male patient without any medical history of sarcoidosis, pancreatic sarcoidosis was the cause of a mass in the head of the pancreas accompanied by an elevation of the tumor marker CA 19-9 (199 U/mL; reference range: 0-37 U/mL). Pancreatic sarcoidosis is extremely uncommon [8, 9]. The first case was described on autopsy in 1937 [10]. Comparable to our case, the patients present with all the signs and symptoms of a pancreatic malignancy, which was confirmed on a CT scan. The CA 19-9 level is also confirmatory of the suspected diagnosis [10]. Comparable to our case, the disease most often presents as a pancreatic head mass. The preoperative
diagnosis of this entity is a clinical challenge, and surgical intervention is usually needed to make a definitive diagnosis [11].

In two male patients (57 and 58 years of age) an asymptomatic mass of 4 cm in the tail of the pancreas was identified as mature teratoma and distal pancreatectomy was performed. In one patient the tumor marker CA 19-9 was elevated (66 U/mL). Teratoma of the pancreas were first described in 1918 by Kerr [12]. They can be classified as benign, well-differentiated lesions, which are solid or cystic, and solid malignant undifferentiated tumors, named, respectively, mature and immature teratomas [13]. Surgical therapy is the only way of guaranteeing definitive resolution [14, 15, 16]. Even though ultrasound, CT and MRI may be helpful, there are no pathognomonic data for their preoperative recognition [17].

A 74-year-old male patient was hospitalized following painful jaundice. MRI and CT showed a double duct sign and a mass of 8 cm diameter in the pancreatic head. Stenting of the common bile duct and diagnostic laparoscopy for taking biopsies was performed at another hospital before. As the mass was suspicious for figure 4.

Figure 4. Capillary hemangioma of the pancreas (arrow). a. Intraoperative photograph. b. Macroscopic photograph. c. Histology of a capillary hemangioma of the pancreas with central regressive changes (arrow) (H&E-staining).

figure 5.

Figure 5. Intrapancreatic accessory spleen (arrow). a. Macroscopic photograph. b. Histology of an accessory intrapancreatic spleen with red and white pulp (arrow) with a fibrous capsule next to normal pancreatic tissue (H&E-staining).
carcinoma and biopsies did not confirm the diagnosis, surgical exploration was done at our department. A large tumorous mass was found in the pancreatic head and peritumorous inflammation involved vessels, stomach and the rest of the pancreas thus total pancreatectomy was carried out. Histological examination of the resected specimen revealed a benign lymphoepithelial cyst of the pancreas. Lymphoepithelial cyst is a rare benign lesion which was described for the first time in 1987 by Truong et al. [18]. Histologically, the lesion has a complex content consisting of keratinous material and a wall lined with mature squamous epithelium surrounded by dense lymphoid tissue [19]. The most common symptoms are abdominal pain, nausea and vomiting, anorexia and weight loss, but many patients are asymptomatic, coming to the surgeon’s attention as incidental radiological finding [19]. Lymphoepithelial cyst may appear either multilocular (60%) or unilocular (40%) as described in our case. The etiopathogenesis as well as histogenesis of lymphoepithelial cyst remain unclear. They have been described in other locations which are associated with autoimmune diseases and states of immunological depression, frequently [20]. Imaging may be not specific and the radiological appearance of these lesions differs. Surgical resection should still be considered the standard therapy, in suitable patients, to exclude malignancy [21]. The prognosis is fairly good. There has never been a report of local recurrence after operative resection.

Another 53-year-old male patient underwent extirpation of a 8 cm diameter asymptomatic hemangioma of the pancreatic head. Pancreatic hemangiomas are extremely uncommon benign pancreatic vascular neoplasms [22]. In contrast to infantile hemangioma - that mostly presents before 6 months of age, grows rapidly, and then regresses spontaneously over several months [23] - adult pancreatic hemangiomas do not regress and reveal a risk of bleeding. As in our case they may not contrast enhance on arterial phase CT imaging [24], thus pancreatic cancer was suspected.

An intrapancreatic accessory spleen was found in a 67-year-old male patient. A mass of 1.5 cm diameter in the pancreatic tail was detected in a routine check-up. Due to a family history of pancreatic cancer (mother and
sister) surgical exploration and distal pancreatectomy were done. Autopsy studies suggest that in 80% the accessory spleen is located at or near the splenic hilum. The second most common site is the pancreatic tail [25, 26]. As in our patient, most often an intrapancreatic accessory spleen is small with a diameter of less than 2 cm [27]. Generally an intrapancreatic accessory spleen does not usually require treatment. Unfortunately, current CT, MRI, and ultrasound technologies do not necessarily distinguish between splenic tissue and pancreatic neuroendocrine neoplasms. Only nuclear medicine examinations/scintigraphy may confirm the diagnosis [28]. Our decision for surgical exploration due to a family history of pancreatic cancer is in line with the statement of Meiler et al. [29] that intrapancreatic accessory spleen is a rare cause of unnecessary laparotomy, but the absence of reliable diagnostics for this entity makes histologic ascertainment of a benign tumor indispensable.

An asymptomatic mass of 5 cm diameter in the processus unciniatus of the pancreas, enlarged peritumoral lymph nodes and a hypodense liver structure (segment VII) suggested a malignant pancreatic tumor in a 67-year-old male patient. MRI showed a stenosis of the pancreatic duct and PET-CT did not show any significantly increased activity. Total pancreatectomy was performed due to a soft fatty pancreatic tissue. Histopathological examination confirmed the diagnosis of a pancreatic hamartoma. A hamartoma is a mass composed of an excess of differentiated cells or mixture of cell types that are normally present in the organ where the mass is found. It may be regarded as a malformation rather than a neoplasm [30]. As in our case nearly all hamartoma arise in the head of the pancreas and tend to affect mostly males [31]. Surgical resection and histopathological examination are required to confirm the diagnosis [31].

In three patients (a 20-year-old female, a 51-year-old female, and a 26-year-old male) a solid pseudopapillary tumor of the pancreas was diagnosed. Solid pseudopapillary tumor (Franz tumor) accounts for less than 1% of all pancreatic tumors [32]. It is of low-grade malignancy but can cause extensive local invasion [33]. Our patients did not show any symptom which is typical for solid pseudopapillary tumors, that are commonly detected incidentally on imaging studies for other reasons [34, 35]. In the male patient a diagnostic biopsy of the tumor, that was carried out before referral to our department, revealed the diagnosis before surgery. The 20-year-old female had a family history of pancreatic cancer (uncle, grandmother). CT and MRCP in all patients showed solid and cystic fractions of the tumor. Butte et al. [36] published data of 45 patients with solid pseudopapillary tumors. Their results demonstrated that solid pseudopapillary tumors primarily occur in young women. Only about 8.3% of all cases were reported in males [37, 38]. About 15% are known to present with metastasis or recurrence [39]. The only feature associated with malignant disease is tumor size (7.8 vs 4.2 cm) at presentation [36]. In our patients tumors had a size between 2 and 4.5 cm and were located at different sites of the organ (head, body, tail). Oncologic explorations in patients who undergo surgical resection are excellent [32]. This is in line with our observations. Until July 2011, 10 to 29 months after operation (Whipple operation, distal pancreatectomy, local excision of the solid pseudopapillary tumor), all patients are in good health without relapse. Surgery including enucleation is typically curative in patients with localized disease and possibly in patients with limited metastasis [40, 41, 42]. No consensus exists on an effective systemic therapy or radiation [43].

In contrast to the above described rare benign intrapancreatic neoplasms, in a 69-year-old female patient, who presented with a mass in the body of the pancreas suspicious for pancreatic cancer, a malignant yolk sac tumor with peritoneal carcinosis and local infiltration of the stomach was diagnosed following surgical exploration. Yolk sac tumor also known as endodermal sinus tumor and Teilum tumor, is one type of germ cell neoplasm. Of all the genital tumors, yolk sac tumors are relatively uncommon and, unlike our case, they are mostly discovered in infants and adolescents (median age: 19 years) [44]. Yolk sac tumor is considered to be a highly malignant tumor that primarily occurs in the testis or ovary [45]. Ten to fifteen percent of these tumors may arise in a variety of midline extravaginal sites. Exceedingly rare sites such as liver, kidney, omentum, stomach, spinal cord and pancreas have been reported [45, 46, 47, 48]. The imaging findings were verified by the morphological observations of an encapsulated tumor with focal necrosis. However in our patient CT was without any pathologic findings. The tumor in the body of the pancreas with a diameter of 3 cm was only detected by endoscopic ultrasound. Since yolk sac tumor usually show high malignancy, the duration from the onset of symptoms to the admission is always short and, as in our patient, metastasis may already exist at the time of the patient’s admission. Surgical excision with combined adjuvant chemotherapy, as it was performed in our patient, is the treatment of choice. However, the prognosis is poor if there is metastasis [45].

Eight patients presented with metastatic tumors to the pancreas (3 renal cell carcinomas, 2 melanomas, 1 duodenal gastrinoma, 1 breast cancer, and 1 retroperitoneal liposarcoma). Metastatic tumors to the pancreas account for less than 2% of all pancreatic malignancies [49]. As with primary pancreatic cancer, early signs and symptoms of isolated pancreatic metastases are often nonspecific and subtle. Patients without symptoms at the time of diagnosis (43%) account for the largest group [49]. In our collective one patient was asymptomatic, four patients complained about abdominal pain, one patient presented with jaundice, one patient with B symptoms (fever, night sweats, weight loss) and the patient with metastatic gastrinoma had diarrhea. Most patients with a
pancreatic secondary tumor are not candidates for resection because they have widespread disease. In our collective in three patients (two patients with renal cell carcinoma and one patient with breast cancer) surgical exploration showed widespread disease and resection was not possible. For improvement of life quality in one of these patients a palliative double bypass was created. Comparable to our observations most pancreatic metastases are referable to renal cell carcinoma [50]. However, metastases from primary lung, breast, colon, skin (melanoma), and sarcoma tumors also involve the pancreas [3]. In accordance with the current literature, metastasectomy with curative intent has become standard practice for the management of metastatic lesions to the liver, lung, and brain from several tumors, with a clear survival benefit [51].

The effectiveness of pancreatic metastasectomy is dependent on the tumor biology of the primary cancer. Renal cell carcinoma is associated with the best outcome, whereas lung cancer predicts the worst outcome [51, 52]. Patients with renal cell cancer may present with metastases to the pancreas many years after the initial diagnosis, emphasizing the need for lifelong surveillance. They can have a good long-term prognosis after surgical resection, with a 5-year survival rate up to 88% in some series [35, 53, 54, 55]. The results of chemotherapy in melanoma are generally disappointing. Presently, surgical resection appears to be the only potentially curative treatment option. However, all metastases have to be excised if surgery is to offer any survival benefit [56]. The survival values after resection of sarcomas are substantially lower than what has been reported for either lung or liver metastasectomies [51]. Nevertheless, pancreatic surgery is considered to be one of the most technically demanding and challenging surgical disciplines and it has been associated with a high rate of mortality and morbidity, which has declined for the past 3 decades. In our collective survival rates were 2 months for renal cell carcinoma, 3 months for melanoma, 4 months for breast cancer, 17 months for sarcoma and 62 months for gastrinoma. Two patients died in the postoperative course: a 67-year-old woman with melanoma died following tumor progress after palliative double bypass and a 64-year-old male patient underwent bleeding of the splenic artery and died after reoperation. One patient had a complicated postoperative course after total pancreaticectomy with pneumonia and renal failure. Three patients underwent curative surgery (2 Whipple operations, 1 distal pancreatectomy) and one patient underwent palliative resection without any complications. Despite the above mentioned morbidity and mortality rates the potential benefit of metastasectomy is documented and it can improve quality of life and survival time being the only chance of cure in selected patients [57, 58].

CONCLUSION

With regard to the presented collective of patients with rare benign and malignant tumors of the pancreas, we conclude, that sometimes even extensive imaging cannot certify the nature of an intrapancreatic tumor. Similar to pancreatic cancer, benign and malignant tumors of the pancreas, intrapancreatic metastasis, pancreatic malformations and abnormalities present as solid masses of the pancreas. Thus, they constitute a differential diagnosis to pancreatic adenocarcinoma. Elevated CA 19-9 levels or a positive family history of pancreatic cancer make malignancy even more likely. Percutaneous or endoscopic ultrasound-guided fine needle aspiration biopsy sometimes can help to distinguish a benign neoplasm from malignant pancreatic tumor [59]. However, there are several reports available on seeding of the needle tract by neoplastic cells and complications such as bleeding, pancreatic fistula and biliary fistula [60]. Steady technical improvement in pancreatic surgery and advances in perioperative supportive care has significantly ameliorated postoperative outcome [61]. Thus, radical resection, which remains the only curative treatment option in adenocarcinoma of the pancreas, can be performed with low mortality and morbidity rates in specialized centers. We conclude that in cases of doubtful dignity, operative exploration, biopsy and when indicated resection of the lesion should be performed. Also for solitary metastases to the pancreas, solid pseudopapillary tumor, yolk sac tumor and symptomatic benign neoplasms of the pancreas there is no satisfactory non-surgical treatment, currently.

Note

Sabine Kersting and Monika S Janot equally contributed to this study

Conflicts of interest

The authors have no potential conflicts of interest

References


